-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

5188 Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Program: Oral and Poster Abstracts
Session: 908. Outcomes Research: Myeloid Malignancies: Poster III
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Clinical Practice (Health Services and Quality), Diseases, Treatment Considerations, Myeloid Malignancies
Monday, December 9, 2024, 6:00 PM-8:00 PM

Rosa Greco1*, Silvia Imbergamo2*, Elisabetta Pierdomenico3*, Barbara Di Camillo4*, Cristina Papayannidis, MD, PhD5, Elisabetta Todisco6*, Erika Borlenghi, MD7*, Nicola Fracchiolla8*, Claudia Basilico9*, Monica Fumagalli, MD10*, Patrizia Zappasodi11*, Mauro Turrini, MD12*, Anna Candoni13*, Monia Lunghi14*, Maurizio Musso15*, Calogero Vetro, MD16*, Fabio Guolo, MD, PhD17, Donato Mannina18*, Albana Lico19*, Anna Maria Scattolin20*, Gianpaolo Nadali21*, Monica Crugnola, MD22*, Sara Galimberti, MD23*, Francesco Marchesi24*, Elisabetta Metafuni25*, Tommaso Caravita di Toritto26*, Clara Minotti27*, Pellegrino Musto28*, Valentina Mancini, MD29*, Marta Riva29*, Lorenzo Rizzo29*, Giovanni Grillo30* and Roberto Cairoli, MD29*

1Hematology Unit, ASST GOM Niguarda, Milano, ITA
2Department of Medicine, Hematology and Clinical Immunology Unit, University of Padova, Padova, Italy
3Hematology Unit, IOV IRCCS, sede di Castelfranco Veneto, Castelfranco Veneto, Castelfranco Veneto, Italy
4Department of Information Engineering, University of Padova, Padova, Italy
5IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
6Hematology, ASST Valle Olona, Ospedale di Busto Arsizio, Busto Arsizio, Italy
7ASST Spedali Civili, Brescia, Department of Hematology, Brescia, Italy
8Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
9Hematology Unit, ASST Sette Laghi-Ospedale di Circolo di Varese e Fondazione Macchi, Varese, Italy
10Hematology Division and Bone Marrow Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
11Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
12Hematology Unit, Division of Hematology, Valduce Hospital, Como, Como, Italy
13Hematology Unit, Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), Udine, Italy
14Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
15Hematology Unit, Clinica La Maddalena Division of Onco-Hematology and Stem Cell Transplantation, Palermo, Italy
16Division of hematology, A.O.U. Policlinico G.Rodolico – S. Marco, Catania, Italy
17Hematology Unit, Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
18Hematology Unit, Messina - Azienda Ospedali Riuniti Papardo-Piemonte - S.C. Ematologia, Messina, ITA
19Hematology Unit, Hematology Unit, San Bortolo Hospital, Vicenza, Italy, Vicenza, Italy
20Hematology Unit, Ospedale Dell Angelo, Mestre, ITA
21Hematology Unit, Azienda Ospedaliera Di Verona, Verona, ITA
22Hematology Unit, University of Parma, Parma, Italy
23Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa, Italy
24Hematology and Stem Cell Transplant Unit, IRCCS - Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (I.F.O.), Rome, Italy
25Hematology Unit, Università Cattolica Del Sacro Cuore, Rome, ITA
26Hematology Unit, Ematologia, Ospedale Santo Spirito ASL Roma1, Roma, ITA
27Department of Translational and Precision Medicine, Division of Hematology, Sapienza University, Rome, Italy
28Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine,and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Bari, Italy
29Department of Hematology and Oncology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
30Department of Hematology and Stem Cell Transplantation, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

Background
The FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation is associated with a poor prognosis in patients with acute myeloid leukemia (AML). Gilteritinib, an oral FLT3 inhibitor, is the first approved monotherapy for relapsed or refractory (R/R) FLT3-mutated AML, demonstrating a survival benefit. The ADMIRAL phase 3 trial showed that gilteritinib monotherapy was superior to standard treatments, including intensive or non-intensive chemotherapy and
hypomethylating therapy with azacitidine. However, real-world data on the efficacy and safety of gilteritinib in clinical practice are limited.

Methods
This study included adult patients (aged >18 years) with R/R AML harboring FLT3 mutations who received salvage therapy with gilteritinib. A retrospective, multicenter, observational study was conducted across 22 Italian centers, identifying 200 patients treated with gilteritinib monotherapy. The treatment period spanned from January 24, 2018, under an early-access program, and from May 31, 2020, as approved by the Italian Drug Agency (AIFA). The study protocol received approval from the ethics committees of all participating centers. This preliminary analysis focuses on 149 patients. Treatment response, event-free survival (EFS) and overall survival (OS) were assessed according to the European LeukemiaNet (ELN) 2017 criteria.

Results
A total of 149 patients with relapsed (n=107) or refractory (n=42) FLT3-mutated AML treated with gilteritinib monotherapy were included in the analysis. Among the refractory patients, 79% were resistant to a single line of therapy, while 21% were resistant to two or more lines. The me
dian age of the patients was 62 years (range: 18-87 years). According to the ELN 2017 classification, 21% of patients had favorable-risk, 36% had intermediate-risk, and 43% had adverse-risk genetic aberrations at initial diagnosis. FLT3 mutations were present at AML diagnosis in 125 patients (84%), while 24 patients (16%) acquired the mutation during the disease course. Among those with FLT3 mutations at diagnosis, 107 out of 125 patients (86%) had FLT3-ITD mutation, 10 patients (8%) had FLT3-TKD mutation, and 8 patients (6%) had both FLT3-ITD and TKD mutations. Additionally, 28% of cases had a concurrent NPM1 mutation. Gilteritinib was administered as a monotherapy to 78 patients (53%), while 71 patients (47%) underwent additional allogeneic hematopoietic stem cell transplantation (alloHCT): 39 patients (26%) received gilteritinib at relapse post-alloHCT, and 32 patients (21%) used gilteritinib as a bridge to transplant. The median number of gilteritinib cycles was four (range: 1-39). In terms of treatment response, 50% of patients achieved complete remission or complete remission with incomplete hematologic recovery (CR/CRi), 13% achieved a partial response, and 33% had progressive or refractory disease. The median duration of response was four months (range: 1-40 months). With a median follow-up of 16.5 months (range: 2.1-67.9 months), the median overall survival (OS) and event-free survival (EFS) for the entire cohort were 10.6 months and 4.64 months, respectively. Patients who received only gilteritinib had a median OS of 7.1 months. The best survival outcomes were observed in patients who underwent alloHCT after gilteritinib treatment, with a median OS of 15.5 months. Similarly, the median EFS was lowest in the gilteritinib-only cohort (4.64 months), with improved outcomes in the group undergoing transplant (6.58 months).

Conclusions
These real-world data align with the results of the ADMIRAL trial, demonstrating that gilteritinib monotherapy is a valuable treatment option for patients with relapsed or refractory FLT3-mutated AML. Notably, patients who underwent allogeneic hematopoietic stem cell transplantation after gilteritinib treatment showed improved survival outcomes, highlighting the potential of gilteritinib as an effective bridge to transplant. Further analysis on complete cohort of 200 patients is ongoing to validate these findings and provide more comprehensive insights into the clinical benefits of gilteritinib in this setting.

Disclosures: Papayannidis: BMS: Honoraria; Servier: Honoraria; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Menarini/Stemline: Honoraria; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Blueprint: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Delbert Laboratories: Membership on an entity's Board of Directors or advisory committees. Borlenghi: Abbvie: Consultancy; Incyte: Other: Travel Grant; BMS: Consultancy; Amgen: Other: Travel Grant. Fracchiolla: Amgen: Speakers Bureau; Jazz: Speakers Bureau; Abbvie: Speakers Bureau; Pfizer: Speakers Bureau. Zappasodi: Amgen: Honoraria; Abbvie: Honoraria; astellas: Honoraria; pfizer: Consultancy, Honoraria. Candoni: Janssen: Honoraria; BMS: Honoraria; Astellas: Honoraria; Pfizer: Honoraria; Abbvie: Honoraria; Incyte: Honoraria. Crugnola: Novartis: Speakers Bureau; BMS: Speakers Bureau. Galimberti: Celgene: Honoraria; Roche: Honoraria, Other: support for attending meetings; Incyte: Honoraria; Novartis: Honoraria, Other: support for attending meetings; Jazz: Honoraria, Other: support for attending meetings; AstraZeneca: Honoraria, Other: support for attending meetings; AbbVie: Honoraria, Other: support for attending meetings; Pfizer: Honoraria; Janssen: Honoraria. Musto: Takeda: Honoraria; Sobi: Honoraria; Sanofi: Honoraria; Roche: Honoraria; Pfizer: Honoraria; Novartis: Honoraria; Jazz: Honoraria; Johnson & Johnson: Honoraria; Incyte: Honoraria; Grifols: Honoraria; Glaxo-Smith-Kline: Honoraria; Gilead: Honoraria; Bristol-Myers Squibb: Honoraria; Bei-Gene: Honoraria; Astra-Zeneca: Honoraria; Astellas: Honoraria; Amgen: Honoraria; Alexion: Honoraria; Abbvie: Honoraria.

*signifies non-member of ASH